Pfizer (PFE) Non-Current Deferred Tax Liability (2009 - 2026)

Pfizer has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $2.4 billion for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 6.82% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (up 6.82% YoY), while the FY2025 annual figure was $2.4 billion, down 81.56% from the prior year.
• Non-Current Deferred Tax Liability held at $2.4 billion in Q1 2026, from $2.4 billion in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for PFE reached as high as $13.0 billion in Q4 2024 and fell as low as $558.0 million in Q3 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $2.2 billion (2024), against an average of $2.7 billion.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability slumped 93.28% — and 2024, when it soared 1934.84%.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $9.5 billion in 2022, then tumbled by 93.28% to $640.0 million in 2023, then soared by 1934.84% to $13.0 billion in 2024, then sank by 81.56% to $2.4 billion in 2025, then climbed by 0.46% to $2.4 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.4 billion, $2.4 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.